AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payme
The received wisdom is that a generation of new products in haemophilia A, led by Roche’s emicizumab and potentially curative gene therapies, will bring about a transformation of treatment
